Altimmune Added to Nasdaq Biotechnology Index
Altimmune (Nasdaq: ALT) announced its addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024. The company's CEO, Vipin K. Garg, highlighted this as an important recognition following a year of major progress. Looking ahead to 2025, the company anticipates significant milestones, including topline data from the Phase 2b IMPACT trial of pemvidutide in MASH expected in Q2. The NBI, established in 1993, tracks Nasdaq-listed biotechnology and pharmaceutical securities that meet specific eligibility criteria including market capitalization, trading volume, and seasoning requirements.
Altimmune (Nasdaq: ALT) ha annunciato la sua inclusione nell'Indice Biotecnologico Nasdaq (NBI), a partire dal 23 dicembre 2024. Il CEO dell'azienda, Vipin K. Garg, ha sottolineato questo come un importante riconoscimento dopo un anno di progressi significativi. Guardando al 2025, l'azienda prevede traguardi significativi, inclusi i dati preliminari del trial IMPACT di Fase 2b su pemvidutide in MASH, attesi nel secondo trimestre. L'NBI, istituito nel 1993, monitora i titoli biotecnologici e farmaceutici quotati al Nasdaq che soddisfano specifici criteri di idoneità, tra cui capitalizzazione di mercato, volume di scambi e requisiti di stagionatura.
Altimmune (Nasdaq: ALT) anunció su incorporación al Índice de Biotecnología Nasdaq (NBI) a partir del 23 de diciembre de 2024. El CEO de la compañía, Vipin K. Garg, destacó esto como un reconocimiento importante tras un año de grandes avances. Con la vista puesta en 2025, la compañía anticipa hitos significativos, incluidos los datos iniciales del ensayo IMPACT de Fase 2b de pemvidutide en MASH, que se esperan en el segundo trimestre. El NBI, establecido en 1993, rastrea los valores biotecnológicos y farmacéuticos que cotizan en Nasdaq y que cumplen con criterios específicos de elegibilidad, como capitalización de mercado, volumen de negociación y requisitos de antigüedad.
Altimmune (Nasdaq: ALT)는 2024년 12월 23일부터 나스닥 생명공학 지수(NBI)에 추가되었다고 발표했습니다. 회사의 CEO인 Vipin K. Garg는 이는 주요 성과를 이룬 해 이후의 중요한 인식이라고 강조했습니다. 2025년을 바라보며, 회사는 2분기에 예상되는 MASH에서 pemvidutide의 2b 단계 IMPACT 시험의 주요 데이터를 포함한 중요한 이정표를 예측하고 있습니다. 1993년에 설립된 NBI는 특정 적격 기준을 충족하는 나스닥 상장 생명공학 및 제약 증권을 추적합니다. 여기에는 시가 총액, 거래량 및 경과 요건이 포함됩니다.
Altimmune (Nasdaq: ALT) a annoncé son ajout à l'Indice Biotechnologique Nasdaq (NBI), effectif à partir du 23 décembre 2024. Le PDG de l'entreprise, Vipin K. Garg, a souligné cela comme une reconnaissance importante après une année de progrès significatifs. En regardant vers 2025, l'entreprise prévoit des jalons importants, y compris des données préliminaires de l'
Altimmune (Nasdaq: ALT) gab bekannt, dass es ab dem 23. Dezember 2024 dem Nasdaq Biotechnologie-Index (NBI) hinzugefügt wird. Der CEO des Unternehmens, Vipin K. Garg, betonte dies als eine wichtige Anerkennung nach einem Jahr bedeutender Fortschritte. Mit Blick auf 2025 erwartet das Unternehmen bedeutende Meilensteine, einschließlich der Topline-Daten der Phase 2b IMPACT-Studie zu pemvidutide in MASH, die für das zweite Quartal erwartet werden. Der NBI, der 1993 gegründet wurde, verfolgt an der Nasdaq notierte Biotechnologie- und Pharmaswerte, die bestimmte Eignungskriterien wie Marktkapitalisierung, Handelsvolumen und Fälligkeitsanforderungen erfüllen.
- Addition to Nasdaq Biotechnology Index (NBI) increases visibility and institutional exposure
- Phase 2b IMPACT trial topline data for pemvidutide expected in Q2 2025
- None.
Insights
The addition to the Nasdaq Biotechnology Index (NBI) represents a technical milestone that could enhance ALT's visibility and liquidity. Inclusion in this index typically requires meeting specific criteria including minimum market capitalization, trading volume thresholds and listing requirements. While index inclusion can lead to increased institutional interest due to passive fund flows from ETFs like IBB that track the index, the news itself is more procedural than fundamentally impactful.
The more significant aspect highlighted in the announcement is the upcoming Phase 2b IMPACT trial data for pemvidutide in MASH (Metabolic Dysfunction-Associated Steatohepatitis) expected in Q2 2025. This clinical milestone, rather than the index inclusion, will be the real catalyst for potential value creation. With a market cap of
GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.
“Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into the new year.”
Established in 1993, the Nasdaq Biotechnology Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as either Biotechnology or Pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NBI must meet certain eligibility requirements, including market capitalization, average daily trading volume and seasoning. The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq: IBB).
For more information about the NASDAQ Biotechnology Index, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI.
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When will Altimmune (ALT) be added to the Nasdaq Biotechnology Index?
When will Altimmune (ALT) release topline data for the pemvidutide MASH trial?
What are the requirements for joining the Nasdaq Biotechnology Index?
What milestone events does Altimmune (ALT) expect in 2025?
